Phase II Single Arm Study of Gemcitabine and Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer

Next Previous
Trial Profile

Phase II Single Arm Study of Gemcitabine and Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Mar 2017 Planned End Date changed from 1 Apr 2020 to 1 May 2024.
    • 10 Mar 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Sep 2019.
    • 01 Jul 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top